The investigation into Corcept Therapeutics for potential securities law violations is significant, as it could lead to legal and financial repercussions. Additionally, Teva's approval to market a generic version of Korlym threatens Corcept's revenue from one of its best-selling products, likely impacting its stock negatively in the short term.